Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure
Trial details
- Registry ID
- NCT02032004
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Allogeneic Mesenchymal Precursor Cells
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart FailureNCT02032004 | Mesoblast, Inc. | Phase 3 | Completed | 2020-01-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |